NTRK1 and ovarian carcinoma: Taken together, these results strongly suggest that monensin may exert its strong anti-proliferative activity by inhibiting growth factor receptor-induced signaling pathways involving the activation of receptor tyrosine kinases, JAK/STAT, MAPK, and/or NFκB downstream signaling mediators in ovarian cancer cells.